June 2020
Volume 61, Issue 7
Free
ARVO Annual Meeting Abstract  |   June 2020
Current and Future Number of Persons Affected by Primary Open-Angle Glaucoma In Mexico.
Author Affiliations & Notes
  • Gabriela Thomassiny
    Ophtalmology, Centro Medico de Ocidente, IMSS, Mexico, Veracruz , Mexico
    Research Department, Unidad de Diagnóstico del Glaucoma, Guadalajara, Jalisco, Mexico
  • Jose A Paczka
    Instituto de Oftalomologia Ciencias Visuales, Universidad de Guadalajara, Guadalajara, Jalisco, Mexico
    Research Department, Unidad de Diagnóstico del Glaucoma, Guadalajara, Jalisco, Mexico
  • Gabriel Riande-Juarez
    Departamento de Investigación en Salud Pública, Universidad Veracruzana, Xalapa, Veracruz , Mexico
  • Luz A. Giorgi-Sandoval
    Research Department, Unidad de Diagnóstico del Glaucoma, Guadalajara, Jalisco, Mexico
    Research Department, Asistencia e Investigación en Glaucoma, Guadalajara, Jalisco, Mexico
  • Footnotes
    Commercial Relationships   Gabriela Thomassiny, None; Jose Paczka, None; Gabriel Riande-Juarez, None; Luz Giorgi-Sandoval, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2020, Vol.61, 59. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Gabriela Thomassiny, Jose A Paczka, Gabriel Riande-Juarez, Luz A. Giorgi-Sandoval; Current and Future Number of Persons Affected by Primary Open-Angle Glaucoma In Mexico.. Invest. Ophthalmol. Vis. Sci. 2020;61(7):59.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Glaucoma is the leading cause of irreversible blindness. Latinos have an increased risk to develop glaucoma. In this population about 75% of the affected persons are undiagnosed. Mexico is the second most populated country in Latin America. The purpose of this study was to determine the current and projected number of people with glaucoma older than 40 years based on the analysis of available epidemiological data.

Methods : Literature search in PubMed was performed including a mixture of keywords (glaucoma, prevalence, epidemiology, Latin America, Latino, Hispanic, Mexican, population, survey). Only four studies characterized by scientific robustness were available; two of them included people either of Mexican nationality or with Mexican ancestry. Prevalence data from Proyecto VER (study 1) and Los Angeles Latino Eye Study (study 2) were the main sources of our analysis. Data extraction was applied according to age and gender stratification using prevalence figures and extrapolating them according to current and projected numbers (2030, 2040 and 2050) of the Mexican population. Information derived from the National Statistical and Mapping Agency of Mexico (INEGI) and CONAPO (National Council on Population) was used.

Results : According to study 1, estimated current number of persons (at least 40 years of age) with glaucoma in Mexico is 854,000 (455,000, female; 399,000, male). In the stratum of age older than 69 years, 123,000 persons could have glaucoma. In 2030, the number of affected people is estimated to be 1.06 million, increasing to 1.27 million in 2040, and to 1.43 million in 2050. Regarding study 2, extrapolated current number of persons with glaucoma in persons older than 40 years is 2 million (1.1 million, female; 900,000, male). In the group older than 69 years, 297,000 persons could have glaucoma. In 2030, the number of people with glaucoma in Mexico was estimated to be 2.5 million, increasing to 3 million in 2040, and to 3.4 million in 2050.

Conclusions : The estimated number of adult people with glaucoma in Mexico will notably increase in the following decades, mainly affecting older people and women. Present and future burden due to glaucoma can significantly impact the Mexican health system, so preventive initiatives must be timely implemented. Data from this report might be helpful to develop proper health policies and effective screening strategies.

This is a 2020 ARVO Annual Meeting abstract.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×